NDAORALSOLUTION
Approved
Jan 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
LYRICA (pregabalin) by Viatris (2) is 2 -delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues. First approved in 2010.
Drug data last refreshed 10h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Pregabalin (LYRICA) is an oral small-molecule anticonvulsant and analgesic that binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system. It reduces pain signaling by modulating neurotransmitter release in the spinal cord and engaging descending pain-modulation pathways. Used primarily for neuropathic pain, postherpetic neuralgia, fibromyalgia, and partial seizures.
$0.072BPart D
LOE ApproachingDeclining
Product approaching loss of exclusivity with 75,632 Part D claims in 2023; commercial teams are transitioning to defensive positioning and cost management.
Mechanism of Action
2 -delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues. Although the mechanism of action of pregabalin has not been fully elucidated, results with genetically modified mice and with compounds structurally related to pregabalin (such as gabapentin)…
Indications
Worked on LYRICA at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.